Mechanical Thrombectomy Devices Market By Product Type (Aspiration Catheters, Stent Retrievers, Mechanical, Rotational and Rheolytic Thrombectomy Systems); By Application (Acute Ischemic Stroke, Pulmonary Embolism, Peripheral Arterial Thrombosis, Deep-Vein Thrombosis and Other Venous Thromboembolism); By End User (Hospitals and Comprehensive Stroke Centers, Specialty Cardiovascular and Neurovascular Centers); By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Mechanical Thrombectomy Devices Market: Procedure-Network Expansion and Multi-Vascular Platforms Reshape Growth

The Global Mechanical Thrombectomy Devices Market was valued at an estimated USD 2.74 billion in 2025 and is projected to reach USD 5.02 billion by 2032, expanding at a CAGR of 9.0% during 2026–2032.

 

Mechanical thrombectomy devices are catheter-based tools used to remove blood clots from cerebral, pulmonary, peripheral arterial, and venous vessels. Major technologies include stent retrievers, aspiration catheters, and mechanical, rotational, or rheolytic systems. Their use varies across stroke, pulmonary embolism, deep-vein thrombosis, and acute limb ischemia, each requiring different specialists, workflows, access systems, and reimbursement pathways.

 

Mechanical thrombectomy devices are minimally invasive catheter-based tools used to remove blood clots and restore blood flow in conditions such as stroke, pulmonary embolism, and other vascular diseases without open surgery. Key systems include Inari’s FlowTriever, Penumbra’s Indigo and Lightning Flash, and neurovascular stent retrievers like Stryker’s Trevo and Medtronic’s Solitaire, along with newer aspiration and navigation-focused devices such as VentiV Pulse, enVast, and Perfuze’s Millipede88. In pulmonary embolism and DVT, FlowTriever and ClotTriever are widely used. Innovation is focused on larger-bore catheters, better suction control, and improved navigation to enhance safety, efficiency, and clot removal with fewer passes.

 

High Thrombotic Disease Burden Supports a Larger Procedure Pool

Stroke remains the largest established application for mechanical thrombectomy. The neurovascular stroke segment accounted for an estimated 67.0% of the market in 2025, equal to USD 1.836 billion. It is projected to reach USD 2.962 billion by 2032 at a CAGR of 7.1%, while its share moderates to about 59.0% as pulmonary and peripheral procedures expand faster.

More than 795,000 people experience stroke annually in the United States, including approximately 610,000 first or new events and 185,000 recurrent strokes. CDC surveillance found that self-reported stroke prevalence increased by 7.8% between the 2011–2013 and 2020–2022 periods, with stronger increases among adults aged 18–64.

The number of patients eligible for thrombectomy is limited because treatment is only performed when imaging confirms a treatable vessel blockage and patients meet strict timing criteria. In the U.S., there are about 718,000 ischemic strokes each year, including roughly 80,000 large-vessel occlusions. However, only around 39,000 mechanical thrombectomy procedures were performed in 2021, covering about 27% of eligible large- and medium-vessel cases.

Cerebral ischemic stroke accounts for about 65%–87% of all strokes globally and in the U.S. In the United States, more than 795,000 people experience a stroke each year, and nearly 87% are ischemic. A stroke occurs roughly every 40 seconds, and stroke-related death happens about every 3 minutes. Overall, about 6.3–7.6 million Americans live with stroke, and ischemic cases make up most events. Globally, there are about 93.8 million people living with stroke and nearly 12 million new cases each year, with ischemic stroke responsible for about two-thirds of cases and over 3 million deaths annually. Around 1 in 4 adults is expected to experience a stroke in their lifetime.

Deep vein thrombosis (DVT) and venous thromboembolism (VTE) also represent a major health burden. In the U.S., up to 900,000 VTE cases occur each year, leading to 60,000–100,000 deaths. DVT incidence is about 80 cases per 100,000 people annually, with higher risk in older adults. Globally, VTE contributes to about 1 in 4 deaths, with incidence rates of 1–2 per 1,000 person-years in Western countries, while being lower in parts of Asia.

Mechanical thrombectomy procedures show high technical success, with vessel recanalization rates of about 80%–94% in acute ischemic stroke cases. However, up to half of patients with successful clot removal still experience poor outcomes due to delayed treatment or severe stroke conditions.

 

Stroke Guidelines Expand Eligibility, but Treatment Capacity Controls Utilization

The 2026 American Heart Association and American Stroke Association guideline supports endovascular thrombectomy for a broader range of selected acute ischemic stroke patients, including certain patients with larger established infarcts and posterior-circulation occlusions. It also emphasizes rapid vascular imaging, coordinated emergency transport, and transfer to thrombectomy-capable centers.

These recommendations can increase the number of patients assessed for intervention, but procedure growth depends on continuous specialist and angiography availability. The American Heart Association’s Target: Stroke Phase III program sets door-to-device targets of 90 minutes for eligible patients arriving directly at thrombectomy-capable hospitals and 60 minutes for transferred patients in at least half of qualifying cases.

Hospitals meeting these targets require standardized imaging protocols, trained emergency teams, predefined transfer pathways, and readily available aspiration catheters, stent retrievers, guide catheters, pumps, tubing, guidewires, and access products. Higher procedure consistency supports inventory turnover, clinician familiarity, and repeat device purchasing.

England illustrates the remaining access gap. Approximately 3,501 thrombectomy procedures were completed during 2023–2024, compared with 2,684 in the preceding year. Despite this increase, only about 4.3% of stroke patients received thrombectomy, while at least 10% were considered potential candidates. The country has 24 comprehensive stroke centers, but seven still lacked full 24-hour thrombectomy coverage in 2026, mainly because of shortages of interventional neuroradiologists, nurses, radiographers, and transfer resources.

Procedure utilization is also rising in continental Europe. Annual thrombectomy procedures in France increased from 2,822 in 2015 to 7,548 in 2019. Mechanical thrombectomy was included in 5.4% of French ischemic-stroke pathways in 2023, while 9.1% involved interhospital transfer. In Germany, the proportion of ischemic-stroke patients receiving thrombectomy rose from 7.1% in 2019 to 8.4% in 2021.

Expansion into distal and medium-vessel occlusions will depend on stronger clinical evidence. Recent findings have shown that thrombectomy does not produce equal benefits across every smaller-vessel occlusion. Manufacturers developing lower-profile devices must demonstrate that improved navigation, vessel compatibility, and clot capture translate into better outcomes in defined patient groups.

 

Pulmonary and Peripheral Thrombectomy Broaden the Market

Pulmonary embolism is emerging as the fastest-growing major application segment. It accounted for an estimated 18.0% of the market in 2025, equal to USD 0.493 billion, and is projected to reach USD 1.255 billion by 2032 at a CAGR of 14.3%. Its share is expected to rise to about 25.0% as pulmonary embolism response teams and dedicated large-bore thrombectomy systems become more widely established.

Treatment is increasingly coordinated by multidisciplinary pulmonary embolism response teams involving interventional cardiology, vascular medicine, radiology, critical care, and cardiac surgery. These teams evaluate hemodynamic instability, right-heart strain, clot burden, bleeding risk, and the suitability of anticoagulation, thrombolysis, surgery, or mechanical clot removal.

The 2026 American Heart Association and American College of Cardiology pulmonary embolism guideline provides a clearer role for catheter-based advanced therapies. Mechanical thrombectomy is considered reasonable for patients in the most severe E1 category and may be considered for selected D1–D2 patients. The guideline also supports multidisciplinary pulmonary embolism response teams, creating a stronger framework for hospital adoption.

Medicare recognizes FDA-cleared transvenous pulmonary embolectomy systems, including FlowTriever and Penumbra Indigo technologies. Pulmonary thrombectomy therefore represents a separate commercial category with larger-bore access requirements, different catheter configurations, blood-management needs, and greater involvement from cardiovascular and critical-care teams.

Peripheral arterial and venous thrombectomy accounted for the remaining estimated 15.0% of the 2025 market, equal to USD 0.411 billion. The segment is projected to reach USD 0.803 billion by 2032 at a CAGR of 10.0%, increasing its market share to approximately 16.0%.

Medicare coverage policies recognize mechanical thrombectomy within acute limb ischemia management, particularly when thrombolytic treatment is unsuitable or rapid revascularization is required. Procedures may combine thrombectomy with angioplasty, stenting, atherectomy, or catheter-directed thrombolysis.

 

Aspiration Platforms Gain from Cross-Indication Use

Aspiration catheters represented the largest product segment in 2025, accounting for an estimated 44.0% share and USD 1.206 billion in revenue. The segment is projected to reach USD 2.410 billion by 2032 at a CAGR of 10.4%, raising its market share to about 48.0% as intelligent aspiration platforms gain use across neurovascular, pulmonary, arterial, and venous procedures.

Aspiration systems have broad cross-indication potential because catheters, pumps, tubing, suction control, and clot-detection functions can be adapted for different vessel sizes. The FDA cleared Penumbra’s Indigo Lightning Flash Select+ catheter in June 2024 for peripheral mechanical thrombectomy. Penumbra System Thunderbolt Aspiration Tubing received neurovascular clearance in June 2026.

These products illustrate the shift toward connected aspiration platforms. Hospitals using proprietary pumps and tubing are more likely to maintain compatible disposable inventory and familiar workflows, strengthening recurring revenue and account retention.

Stent retrievers accounted for an estimated 38.0% of the market in 2025, representing USD 1.041 billion. Revenue is projected to reach USD 1.707 billion by 2032 at a CAGR of 7.3%, while share declines to about 34.0% because aspiration and pulmonary thrombectomy platforms are expanding faster. Stent retrievers remain central to neurovascular thrombectomy and are frequently used alone or with aspiration. Development is focused on radial force, cell architecture, visibility, vessel-size compatibility, trackability, and the ability to retrieve different clot types without causing vessel injury.

The FDA cleared phenox’s pRESET Delta and pRESET Delta LITE devices in February 2025. The clearance shows that retriever design and vessel compatibility remain important areas of differentiation within the established neurovascular segment.

Mechanical, rotational, and rheolytic systems accounted for an estimated 18.0% share and USD 0.493 billion in 2025. The segment is projected to reach USD 0.904 billion by 2032 at a CAGR of 9.0%, maintaining an approximately 18.0% share as demand grows in peripheral and venous procedures.

Comparative evidence has not established a universally superior first-pass approach between direct aspiration and stent-retriever-first treatment. Device selection continues to depend on vessel anatomy, clot characteristics, catheter access, physician experience, and rescue-treatment requirements. Suppliers therefore compete through navigation, aspiration efficiency, first-pass performance, system compatibility, training, and procedural consistency.

Penumbra’s financial performance reflects volume-led expansion. Global thrombectomy revenue reached USD 259.0 million in the second quarter of 2026, increasing 12.5% from USD 230.3 million a year earlier. First-half revenue reached USD 512.9 million, up 12.3%, primarily through higher U.S. sales volume and product penetration while pricing remained largely unchanged.

 

Regulatory Oversight Raises Product-Quality Requirements

Mechanical thrombectomy devices generally enter the U.S. market through Class II regulatory pathways linked to defined vessel anatomies and clinical indications. Performance in a peripheral vessel does not establish suitability for neurovascular use because catheter diameter, aspiration pressure, radial force, access route, and vessel-wall interaction differ materially.

FDA clearance activity across pRESET Delta, Lightning Flash Select+, and Thunderbolt Aspiration Tubing shows continued investment in retrieval mechanics, catheter dimensions, aspiration control, and system integration.

Post-market performance also affects hospital confidence. The FDA classified a 2025 recall involving the Artix MT device as Class II after product labeling stated an incorrect vessel-size range of 2.5–6 millimeters instead of 3–6 millimeters. The error could expose smaller vessels to excessive radial force.

 

Regional Market Analysis

North America led the market with an estimated 43.0% share in 2025, equivalent to USD 1.178 billion. The regional market is projected to reach USD 2.008 billion by 2032 at a CAGR of 7.9%, retaining leadership with an estimated 40.0% share. Its position reflects established stroke care networks, favorable reimbursement, specialist hospitals, and early adoption of thrombectomy in both stroke and pulmonary embolism.

The U.S. records over 795,000 strokes annually, but only a fraction of eligible large-vessel occlusion patients receive thrombectomy, supporting further growth as access and hospital capacity expand. Penumbra also highlights the region’s importance, with 78.3% of its second-quarter 2026 revenue coming from U.S. customers.

Europe accounted for an estimated 29.0% of the market in 2025, equal to USD 0.795 billion. It is projected to reach USD 1.406 billion by 2032 at a CAGR of 8.5%, representing about 28.0% of global revenue. England performed 3,501 thrombectomies in 2023–2024, treating fewer than half of the estimated eligible proportion of patients. Germany increased treatment rates from 7.1% to 8.4% of ischemic-stroke cases between 2019 and 2021, while France continues to expand procedure volumes. Growth depends on better 24-hour coverage, specialist availability, and stronger regional stroke centers.

Asia-Pacific represented an estimated 23.0% share and USD 0.630 billion in 2025. It is projected to be the fastest-growing region, reaching USD 1.355 billion by 2032 at a CAGR of 11.6% and increasing its share to approximately 27.0%. Australia’s 2023 audit showed gaps in access, with some major stroke centers lacking full thrombectomy availability. China, Japan, South Korea, and India are expanding stroke networks, but access remains limited outside major cities due to workforce shortages, reimbursement differences, and transport delays.

The remaining regional markets accounted for approximately 5.0% of global revenue in 2025, equal to USD 0.137 billion, and are projected to reach USD 0.251 billion by 2032 at a CAGR of 9.0%. Growth will remain concentrated in countries investing in advanced stroke centers, vascular intervention capacity, and emergency transfer systems.

 

Competitive Landscape

Competition is shifting from stand-alone products toward multi-vascular thrombectomy portfolios. Leading manufacturers are seeking positions across stroke, pulmonary embolism, venous thrombosis, and peripheral arterial intervention.

Stryker completed its approximately USD 4.9 billion acquisition of Inari Medical in February 2025. The transaction added FlowTriever and ClotTriever to Stryker’s established neurovascular business, giving the company access to pulmonary and venous thrombectomy.

Boston Scientific agreed in January 2026 to acquire Penumbra for USD 374 per share, representing an enterprise value of approximately USD 14.5 billion. The transaction would combine Penumbra’s aspiration and neurovascular technologies with Boston Scientific’s cardiovascular distribution and interventional portfolio. An FTC request for additional information indicates regulatory scrutiny of the competitive effects of the transaction.

Penumbra, Stryker, Inari Medical, phenox, Medtronic, Johnson & Johnson’s Cerenovus, and other neurovascular and peripheral-intervention companies compete through catheter performance, device deliverability, clinical evidence, physician training, regulatory execution, and hospital-account coverage. Broader portfolios allow manufacturers to serve several departments, bundle complementary products, and increase recurring disposable revenue.

 

Analyst Perspective

Mechanical thrombectomy revenue growth is driven mainly by higher procedure volumes rather than pricing. Key opportunities include treating more eligible stroke patients, expanding 24-hour thrombectomy coverage, growing pulmonary embolism response programs, and broader use of aspiration-based systems across vascular conditions.

The segment outlook shows how the revenue mix is changing. Neurovascular stroke remains the largest application, but pulmonary embolism is projected to grow more than twice as fast. Aspiration catheters are expected to gain four percentage points of product share by 2032, while Asia-Pacific gains four percentage points of regional share as specialist capacity expands.

Growth is still limited by system readiness. Hospitals need fast imaging, trained specialists, reliable transfer pathways, available procedure rooms, stocked devices, and clear reimbursement to convert emergency cases into treatment.

 

Mechanical Thrombectomy Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 2.74 Billion
Revenue Forecast in 2032	USD 5.02 Billion
Overall Growth Rate	CAGR of 9.0% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Aspiration Catheters, Stent Retrievers, Mechanical, Rotational and Rheolytic Thrombectomy Systems
By Application	Acute Ischemic Stroke, Pulmonary Embolism, Peripheral Arterial Thrombosis, Deep-Vein Thrombosis and Other Venous Thromboembolism
By End User	Hospitals and Comprehensive Stroke Centers, Specialty Cardiovascular and Neurovascular Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising stroke and venous thromboembolism burden, expansion of thrombectomy-capable care networks, broader pulmonary embolism applications, growing adoption of aspiration platforms, and improved emergency transfer pathways
Customization Option	Available upon request